Last reviewed: June 21, 2026
Last updated: June 21, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide therapy typically begins with a 0.25 mg subcutaneous injection once weekly, a deliberate starting point proven safe in major clinical trials. This foundational dose allows your body to adapt while minimizing nausea and gastrointestinal side effects. PlexusDx provides compounded semaglutide injections from licensed 503A pharmacies, starting at $149 per month, with built-in flexibility as your dose increases.
Why Semaglutide Starts at 0.25 mg: The Clinical Foundation
The 0.25 mg opening dose in semaglutide therapy reflects decades of pharmacology research and real-world patient data. This micro-dose activates glucagon-like peptide-1 receptors in your brain's appetite centers while keeping adverse events minimal. Starting low protects your gastrointestinal system from sudden hormonal shifts and gives you time to recognize how your body responds to GLP-1 receptor activation.
Clinical trials leading to FDA approval used this tiered approach precisely because it works. Your body needs a chance to upregulate GLP-1 signaling gradually. Jumping to higher doses increases nausea risk without improving weight loss speed. PlexusDx physicians design your dose escalation schedule based on your tolerance and metabolic markers, not arbitrary timelines.
The Four-Week Dose Escalation Protocol
Standard semaglutide therapy follows a predictable progression: 0.25 mg weekly for four weeks, then 0.5 mg weekly for four weeks, followed by incremental increases to 1.0 mg, 1.7 mg, and finally 2.4 mg. This staggered approach, used in SUSTAIN trials, reduced treatment discontinuation due to side effects by over 40 percent compared to faster escalations. Each monthly step gives your pancreas and intestines time to recalibrate glucose signaling.
Your dose may need to go up; your price won't. PlexusDx charges a flat monthly rate regardless of which escalation tier you're on—the same $149 starting price covers your entire dose optimization journey. This transparent model removes the guesswork about whether increasing your dose will suddenly cost more.
Individual Response Variation and Genetic Personalization
Not every patient responds to semaglutide at the same dose. Genetic variation in the GLP1R gene (rs6923761 variant) influences how efficiently your cells bind GLP-1 molecules. Some individuals achieve significant appetite suppression at 0.5 mg weekly, while others require 1.7 mg or higher to reach therapeutic benefit. The Precision Peptide Genetic Test from PlexusDx maps 14 metabolic pathways across 49 peptides, revealing your genetic predisposition to GLP-1 sensitivity before you start injecting.
Knowing your GLP1R status, GIPR rs1800437 variant status, and FTO rs9939609 genotype empowers you and your clinician to predict whether you'll be a fast responder or need more gradual titration. This 10-minute genetic assessment, available as a $99 add-on after your first month, eliminates months of trial-and-error dosing. PlexusDx integrates these insights into your personalized protocol.
Managing Side Effects During Your Starting Dose
The 0.25 mg dose intentionally sits below the nausea threshold for most patients. Roughly 25 percent of people report mild nausea in week one, which typically resolves by week three as your stomach adapts. Eating smaller, frequent meals and staying hydrated supports your body's adjustment. Severe nausea at the starting dose is rare and usually signals an underlying food sensitivity or medication interaction—reasons to reach out to your PlexusDx clinician immediately.
Constipation appears more frequently than nausea at any semaglutide dose because the drug slows gastric emptying. Increasing fiber intake gradually, drinking 80–100 ounces of water daily, and adding a stool softener prevents this common complaint. Your PlexusDx provider shares a side-effect management guide with your first shipment, including dietary adjustments and over-the-counter remedies that work alongside GLP-1 therapy.
How Long Until You Notice Weight Loss Results?
Weight loss typically becomes measurable between weeks four and eight on semaglutide, once your dose reaches 0.5 mg or higher. Early trials showed average monthly losses of 1–2 pounds in month two, accelerating to 2–4 pounds monthly by month four at higher doses. Individual results vary based on your starting weight, diet adherence, exercise habits, and those genetic markers your Precision Peptide test reveals. Expecting dramatic change in your first two weeks sets unrealistic expectations; the drug works best when you view it as a six-month commitment.
PlexusDx tracks your progress through monthly check-ins, body composition assessments, and appetite logging. Your clinician adjusts your dose up or down based on actual results, not assumptions. If you're not losing weight by week 12, genetic factors or medical conditions might explain why—that's when the Precision Peptide test becomes especially valuable for course correction.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the minimum dose of semaglutide I should start with?
The standard minimum starting dose is 0.25 mg injected subcutaneously once weekly. This dose activates GLP-1 receptors safely while your body adapts. PlexusDx prescribes this foundational dose to all new patients, with increases scheduled every four weeks based on tolerance and weight loss progress.
Why doesn't semaglutide start at a higher dose like 1.0 mg?
Starting at 0.25 mg minimizes nausea and gastrointestinal distress, which were the primary reasons patients discontinued treatment in clinical trials. Gradual escalation allows your metabolic hormones to rebalance progressively, improving long-term adherence and safety outcomes.
Does my price increase when my semaglutide dose goes up?
No. PlexusDx charges a flat $149 per month for compounded semaglutide injections from licensed 503A pharmacies, whether you're at 0.25 mg or 2.4 mg. Your dose may need to go up; your price won't—that's the PlexusDx commitment to transparent, predictable costs.
How quickly can I increase my semaglutide dose?
Standard escalation increases your dose by 0.25 mg every four weeks until you reach your therapeutic target, typically 1.7–2.4 mg. Faster increases raise nausea risk without improving results. PlexusDx can customize escalation timelines if you experience side effects, allowing 6–8 week intervals between increases.
Can the Precision Peptide Genetic Test predict my ideal starting dose?
Yes. Your GLP1R rs6923761 variant, GIPR rs1800437 status, and FTO genotype influence how sensitively you respond to semaglutide. The $99 Precision Peptide test maps these and 47 other peptide-pathway markers, helping your PlexusDx clinician predict whether you'll be a fast responder or need extended low-dose timing, enabling personalized dosing from week one.
What happens if I don't tolerate 0.25 mg semaglutide?
Severe intolerance at the starting dose is uncommon but treatable. PlexusDx can extend your time at 0.25 mg beyond four weeks, reduce injection frequency temporarily, or explore oral semaglutide as an alternative. Your clinician also reviews medications and food sensitivities that might amplify side effects.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Why Did I Gain Weight on Wegovy? Understanding the Factors Behind Weight Fluctuations
What Has Less Side Effects: Ozempic or Wegovy?